Evaluación de la fatiga en pacientes con artritis psoriásica y su asociación con otras variables de la enfermedad

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Objetivo: Evaluar la frecuencia de fatiga en pacientes con APs y su asociación con otras variables de la enfermedad. Métodos: Pacientes ≥18 años con diagnóstico de APs según criterios CASPAR. Se evaluó fatiga, rigidez matinal, dolor, actividad de la enfermedad por el paciente y el médico por escala visual graduada (EVG). Se completaron los autocuestionarios ASQoL, PsAQoL, HAQ-A, BASFI y BASDAI. Se calcularon los índices compuestos DAS28, DAPSA y CPDAI. Resultados: Se incluyeron 112 pacientes. La mediana de fatiga fue de 3 cm (RIC 0-6). Fatiga tuvo aceptable correlación con BASDAI (r:0,63), pregunta Nº1 del BASDAI (r:0,48), DAS28 (r:0,45), DAPSA (r:0,5), HAQ-A (r:0,42), PsAQoL (r:0,49), ASQoL (r:0,48), BASFI (r:0,47), EVG de dolor (r:0,48) y de rigidez matinal (r:0,55). El 30% de nuestra cohorte presentó fatiga definida como EVG ≥6 cm. En el análisis de regresión lineal múltiple, la actividad de la enfermedad articular periférica (DAPSA coef β: 0,36, p=0,0001) y la calidad de vida (PsAQoL coef β: 0,27, p=0,009) se asociaron significativamente a fatiga. Conclusión: El 30% de nuestra cohorte de pacientes presentó EVG de fatiga ≥6 cm. La fatiga se asoció independientemente con la actividad de la enfermedad articular periférica y la calidad de vida.

Translated abstract

Objective: To evaluate the frequency of fatigue in patients with PsA and its association with other disease variables. Methods: We included patients ≥18 years of age with PsA according to CASPAR criteria. Fatigue, morning stiffness, pain and global activity by both patients and physicians were assessed using visual analogue scales (VAS). ASQoL, PsAQoL, HAQ-A, BASFI and BASDAI were completed. DAS28, DAPSA and CPDAI were calculated. Results: We included 112 patients. Median fatigue VAS was 3 cm (IQR 0-6). Fatigue had an acceptable correlation with BASDAI (r:0.63), BASDAI question Nº1 (r:0.48), DAS28 (r:0.45), DAPSA (Rho:0.5), HAQ-A (Rho:0.42), PsAQoL (Rho:0.49), ASQoL (Rho:0.48), BASFI (Rho:0.47), pain (Rho:0.48) and morning stiffness (Rho:0.55) and a regular correlation with CPDAI (Rho:034). 30% of our cohort had fatigue, as defined by a VAS equal or greater than 6 cm. In multiple linear regression analysis, adjusting for sex, age and disease duration, peripheral disease activity (DAPSA βcoeff: 0.36, p=0.0001) and quality of life (PsAQoL βcoeff: 0.27, p=0.009) were associated with fatigue. Conclusion: Prevalence of fatigue in this cohort was 30% and it was associated with greater peripheral disease activity and worse quality of life.

Related collections

Most cited references 22

Record: found
Abstract: found
Article: not found

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

D Felson, J. Anderson, M. Boers … (1993)

To develop a set of disease activity measures for use in rheumatoid arthritis (RA) clinical trials, as well as to recommend specific methods for assessing each outcome measure. This is not intended to be a restrictive list, but rather, a core set of measures that should be included in all trials. We evaluated disease activity measures commonly used in RA trials, to determine which measures best met each of 5 types of validity: construct, face, content, criterion, and discriminant. The evaluation consisted of an initial structured review of the literature on the validity of measures, with an analysis of data obtained from clinical trials to fill in gaps in this literature. A committee of experts in clinical trials, health services research, and biostatistics reviewed the validity data. A nominal group process method was used to reach consensus on a core set of disease activity measures. This set was then reviewed and finalized at an international conference on outcome measures for RA clinical trials. The committee also selected specific ways to assess each outcome. The core set of disease activity measures consists of a tender joint count, swollen joint count, patient's assessment of pain, patient's and physician's global assessments of disease activity, patient's assessment of physical function, and laboratory evaluation of 1 acute-phase reactant. Together, these measures sample the broad range of improvement in RA (have content validity), and all are at least moderately sensitive to change (have discriminant validity). Many of them predict other important long-term outcomes in RA, including physical disability, radiographic damage, and death. Other disease activity measures frequently used in clinical trials were not chosen for any one of several reasons, including insensitivity to change or duplication of information provided by one of the core measures (e.g., tender joint score and tender joint count). The committee also proposes specific ways of measuring each outcome. We propose a core set of outcome measures for RA clinical trials. We hope this will decrease the number of outcomes assessed and standardize outcomes assessments. Further, we hope that these measures will be found useful in long-term studies.

0 comments Cited 187 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Assessment of enthesitis in ankylosing spondylitis.

R Landewé, Marcory van Dijk, Robrecht van der Wel … (2003)

To assess, firstly, the validity of the enthesis index published by Mander (Mander enthesis index (MEI)) and, secondly, to investigate whether it is possible to define a new enthesis index that is less time consuming to perform with at least similar or better properties. Data from the OASIS cohort, an international, longitudinal, observational study on outcome in ankylosing spondylitis, were used. In this study, measures of disease activity, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the MEI, were assessed regularly in 217 patients. With the MEI, for each measurement period independently, a process of data reduction was performed to identify the entheses most commonly reported as painful by the patients. A more concise enthesis index was constructed with aid of the entheses found in this way. Correlations with measures of disease activity were used to test the validity of several entheses indices. Reduction of the number of entheses from 66 to 13 and omitting grading of the intensity of pain resulted in an index which was named the "Maastricht Ankylosing Spondylitis Enthesitis Score" (MASES). The MASES (range 0-13) has much greater feasibility than the MEI (range 0-90). However, up to 21% of patients with a score >0 on the MEI were not identified by a score on the MASES >0. Only 2.1% of the patients with an original enthesis score >0 had an original score on the MEI >3 (range 0-90) and it can be questioned whether a low score on the MEI index represents clinically important enthesitis. The Spearman correlation coefficient between the MASES score and the MEI was 0.90 and between the MASES and the BASDAI was 0.53 compared with a correlation of 0.59 between the MEI and the BASDAI. MASES seems to be a good alternative to the MEI with much better feasibility.

0 comments Cited 142 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.

Cheryl Rosen, Farheen Mussani, Vinod Chandran … (2012)

PsA is an inflammatory arthritis present in ∼30% of people with psoriasis (PsC). Both conditions have a significant impact on quality of life (QoL). Our objective was to test the hypothesis that people with PsA have poorer QoL than patients with PsC because of the added burden of arthritis, age and comorbidities. Consecutive patients with PsA (CASPAR criteria) and PsC were approached to participate in this study. Patients with PsC were examined by a rheumatologist using a standardized protocol to exclude PsA. Patients completed the HAQ, Medical Outcome Study 36-item Short Form Health Survey, Dermatology Life Quality Index (DLQI), EuroQoL 5 domains (EQ-5D) and Fatigue Severity Scale (FSS). Mean scores were compared and multivariate analyses were conducted to compare the QoL measures between the two patient groups. Two hundred and one patients with PsC and 201 patients with PsA were studied. A significant decrease in QoL for patients with PsA compared with those with PsC was identified by all questionnaires except for the DLQI. This skin-specific questionnaire revealed a lower QoL in patients with PsC. Multivariate analyses for each QoL measure confirmed the results of these analyses. After adjusting for age, sex, duration of PsC, comorbidities, DMARDs and biologic therapy, HAQ and DLQI were independently associated with PsA in a logistic regression. Patients with PsA have a poorer QoL compared with those with PsC as measured by all questionnaires except the DLQI.

0 comments Cited 77 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

J. Gallino Yanzi: Role: ND

O. Cerda: Role: ND

C.A. Zaffarana: Role: ND

M. Landi: Role: ND

E.E. Schneeberger: Role: ND

I. Carrillo: Role: ND

M.C. González Guzmán: Role: ND

M.P. Kohan: Role: ND

E. Buschiazzo: Role: ND

J.A. Maldonado Cocco: Role: ND

G. Citera: Role: ND

Journal

Journal ID (publisher-id): reuma

Title: Revista argentina de reumatología

Abbreviated Title: Rev. argent. reumatolg.

Publisher: Sociedad Argentina de Reumatología (Buenos Aires, , Argentina )

ISSN (Print): 0327-4411

ISSN (Electronic): 2362-3675

Publication date (Print and electronic): September 2016

Volume: 27

Issue: 3

Pages: 16-20

Affiliations

[02] CABA orgnameHospital Dr. E. Tornú Argentina

[03] Salta orgnameHospital Señor del Milagro Argentina

[01] CABA orgnameInstituto de Rehabilitación Psicofísica Argentina

Article

Publisher ID: S2362-36752016000300003

SO-VID: edcb6d5e-2876-408a-baaf-123351b58595

License:

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

History

Page count

Figures: 0, Tables: 0, Equations: 0, References: 33, Pages: 5

Product

SciELO Argentina

Keywords: artritis psoriásica,fatiga,psoriatic arthritis,fatigue

Data availability:

Keywords: artritis psoriásica, fatiga, psoriatic arthritis, fatigue

Comments

Comment on this article

Most referenced authors 541

See all reference authors